Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for May 2007
May 1, 2007
- Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014
- Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
- New Hampshire Law Banning Commercial Use of Prescription Information Declared Unconstitutional
- Ista Pharma Ltd Withdraws Its Marketing Authorisation Application for Vitragan
- Lilly to Publish Information on Grants and Contributions
- IMPAX Reports SEC Actions
- MedImmune Reports Financial Results for 2007 First Quarter
- Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
- FDA Warns Consumers About Counterfeit Drugs From Multiple Internet Sellers
- Baxter Executives Provide Update on Progress at Annual Shareholder Meeting
- Inex Pharmaceuticals Announces Completion of Spin-out of Tekmira Pharmaceuticals Corporation
- Eurand Files IPO Registration Statement with SEC
- First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
- Physicians Practice Acquired by United Business Media
May 2, 2007
- Biogen Idec Reports First Quarter 2007 Results
- Teva Reports First Quarter 2007 Results
- CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
- FDA Approves Oscient Pharmaceuticals' Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
- FDA Advisory Committee Finds Substantial Evidence to Support Advair 500/50 in Reducing COPD Exacerbations
- FDA Approves Fragmin as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
- Novo Nordisk: Financial statement for the period 1 January 2007 to 31 March 2007 (2 May 2007)
- Pfizer Launches Online Initiative Disclosing Its U.S. Post-Marketing Commitments
- Bristol-Myers Squibb Breaks Ground on New Biologics Manufacturing Facility in Massachusetts
- FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
- Sunesis Pharmaceuticals Announces Preclinical Milestone Payment in BACE Collaboration with Merck
- Allergan Reports First Quarter Operating Results
- New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
May 3, 2007
- Vyvanse (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
- sanofi-aventis: Full-year Guidance Raised on Good 2007 First-Quarter Results
- Medarex to Receive Milestone Payment from Amgen
- Statement by Merck & Co., Inc., Regarding the Fracture Intervention Trial with Fosamax (alendronate sodium) and Incidence of Atrial Fibrillation
- Morgan Keegan To Acquire Shattuck Hammond Partners
- GPC Biotech Consolidates Drug Discovery Activities
- Medicis Announces FDA Approval of Perlane
- Mylan Announces Tentative FDA Approval for Letrozole Tablets, USP
- GPC Biotech AG (DE) - GPC Biotech Consolidates Drug Discovery Activities
- Senate Committee on Finance Responds to ACCME
- Takeda Pharmaceutical First Sponsor In New Healthcare Broadband Platform
- Former Serono Employee Not Guilty in Health Care Fraud Case
May 4, 2007
- Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
- Rx for Africa, Inc. Announces Merger with Rx Africa (Ethiopia) PLC and Diamond Entertainment Corporation
- Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
- Schering-Plough Receives Request for Additional Information From Federal Trade Commission in Connection With Planned Organon Biosciences N.V. Transaction
- Pharmaceutical Whistleblowers Tell Their Tales Through Blogs, Congress Responds
- Merck & Co., Inc. Statement on Brazilian Government's Decision To Issue Compulsory License for Stocrin
- MarketResearch.com Acquires Thomson Business Intelligence (TBI) Market Research (Profound) Service
- Devax, Inc. Files Registration Statement for Proposed Initial Public Offering
May 7, 2007
- FDA Advises Manufacturers to Test Glycerin for Possible Contamination
- Takara Bio Grants Transgenomic License for LA-PCR Technology
- Adverse Event of FG-2216 for the Treatment of Anemia
- Overseas Co-Promotion of Actemra, a Treatment for Rheumatoid Arthritis
- Official Completion of New Patient Enrollment of Post Marketing Surveillance on Enbrel Shows Encouraging Results for Patients and Physicians
- CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
- Affitech Signs Antibody Research and Licensing Agreement with Roche
- Peptech and Evogenix Merge to Form Antibody Powerhouse
- Bayer HealthCare and Intendis Announce Strategic Alliance to Co-Promote Yaz (Drospirenone/Ethinyl Estradiol) for Treatment of Moderate Acne
- Pfizer Partners with Canadian Policymakers to Continue Shaping an Environment Conducive to Research and Innovation
- AstraZeneca to Begin Construction for $100M Research Investment at R&D Boston; Expansion Solidifies Company's Commitment to Massachusetts as a Scientific and Biotech Hub
- Viragen Shifts Development Focus for Anti-Cancer Products
- USA for Innovation Launches ThaiLies.com
May 8, 2007
- inVentiv Health Announces Executive Management Changes
- AARP Welcomes Senate Passage of Rx Importation, but Promises to Fight Unnecessary Importation Roadblocks
- AARP Welcomes Senate Passage of Rx Importation, but Promises to Fight Unnecessary Importation Roadblocks
- AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication
- AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication
- Solvay Group First Quarter 2007 Results
- CEOS Up $1.26 Billion, Shareholders Down $330 Billion
- Bayer Publishes Interim Report for the First Quarter of 2007
- Bradley Pharmaceuticals Announces Resignation of Dr. Leonard S. Jacob as Non- Executive Chair, Appointment of Seth W. Hamot as Interim Non-Executive Chair
- Medicis Pharmaceutical to Pay U.S. $9.8 Million to Resolve False Claims Allegations
- Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension, 250 mg/5 mL, Launches Entire Product Family
- Singapore Attracts Four Major Biologics Manufacturing Investments Totaling Close to US$1 Billion in Less Than Two Years
May 9, 2007
- Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
- Study by Cardiologists at Northwestern Memorial Reveals a High Percentage of Heart Patients Receive Off-Label and Untested Drug-Coated Stents
- Lilly Announces New Employee Policy
- Hospira Reports First-Quarter 2007 Results
- Somaxon Pharmaceuticals Provides Update on Silenor Development Program
- FDA Re-Inspection Results in Positive Re-Classification of Guayama Facility
- Abbott Highlights Strong Performance in Corporate Social Responsibility in 2006 Global Citizenship Report
- Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
May 10, 2007
- Biosite Receives Revised Offer From Inverness Medical Regarding Possible Cash Tender Offer
- King Pharmaceuticals Reports First-Quarter 2007 Financial Results
- FDA Sends Letter to GlaxoSmithKline Regarding Flonase Aid
- FDA Sends Letter to Schering Over Nasonex Detail Aid
- Statement of Purdue Pharma Regarding Resolution of the Federal Investigation in the Western District of Virginia
- Gene Logic and Abbott Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
- Dendreon Reports First Quarter 2007 Financial Results
May 11, 2007
- Asterand plc, Bristol-Myers Squibb Sign Further Agreements for Access to Asterand Products and Services
- Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal Antitrust Investigation
- Pharmaceutical Bloggers Busy This Week with Discussions of FDA Revitalization Act and Off-label Marketing
May 14, 2007
- Teva Comments About the Acquisition of Merck KGaA Generic Business
- Mylan Laboratories to Acquire Generics Business of Merck KGaA
- Eisai Obtains Favorable Ruling in Aciphex Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories
- Cardinal Health to Acquire Medical Technology Leader VIASYS Healthcare for $1.5 Billion
- Southern District Court of New York Rules Patent for Aciphex Enforceable
- Biovail Acknowledges Receipt of Wells Notice
- Oral Pleadings in Implanon Appeal
- Recall of Two Valproic Acid Drugs, Depakene 500 mg and Ratio-Valproic 500 mg
- Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD
- Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer
- P&G Announces Business Unit Realignment
May 15, 2007
- King Pharmaceuticals Receives DHS Safety Act Designation and Certification for AtroPen
- Eisai Signs Exclusive Agreement to Commercialize NeuroBloc for Europe
- President and CEO of Advanced Viral Research Corp. Signs on for an Additional Two Years
- Sanofi-Aventis Calls for an Effective Policy Against Drug Counterfeiting
- GSK Returns Development Rights for MED2002
- Results Mixed on Postmarketing Studies of New Drugs, According to the Tufts Center for the Study of Drug Development
- Commonwealth Biotechnologies, Inc. Announces Definitive Agreement to Acquire Tripos Discovery Research Ltd
- Proteros Biostructures and Boehringer Ingelheim Pharmaceuticals Enter into Protein Crystallography Agreement
May 16, 2007
- Biovail Acknowledges Wells Notices Received by Company Executives
- Wyeth Wins Philadelphia Hormone Therapy Trial
- Biovail Chairman Eugene Melnyk Announces Retirement
- Increases in Medication Use Among 10 to 19 Year-old Girls for Several Chronic and Behavioral Conditions Far Outpaces Boys of the Same Age
- Bausch & Lomb Enters into Merger Agreement with Warburg Pincus
- Bausch & Lomb Enters into Merger Agreement with Warburg Pincus
- pSivida Redeems Convertible Note Debt
- Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is Not Supported by the Evidence'
- Corporate Philosophy and Vision, Brand Mark, Business Management Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation
May 17, 2007
- AAIPharma Strengthens South American Operations through Acquisition of Instituto de Pesquisa Clinica de Sao Paulo, Ltd.
- Cardinal Health Names Scott Storrer Group President, Healthcare Supply Chain Services-Pharmaceutical
- New Report: Unmanaged, Diabetes Drug Costs Could Surge Nearly 70 Percent Within Three Years
- ImmunoGen, Inc. Announces Resignation of Howard Pien from its Board of Directors
- Dramatic Cost Discrepancies Revealed in AG's Investigation of Drug Prices Statewide
- 10th Annual National Survey On Consumer Reaction To DTC Pharmaceutical Advertising Reveals #1 Action Taken After Seeing DTC Ad:
May 18, 2007
- New Report: Unmanaged, Diabetes Drug Costs Could Surge Nearly 70 Percent within Three Years
- Britain's NAO: Prescribing Costs in Primary Care
- Pharmaceutical Industry Remains Anxious About Challenges Presented by Blogs and Michael Moore’s Latest Documentary
May 21, 2007
- KineMed Evaluates the Mechanism of Action for Colesevelam in Patients With Type 2 Diabetes
- Talabostat Clinical Program Put on Clinical Hold by FDA
- AMRI Acquires Manufacturing Facilities in India
- Tibolone Study in Breast Cancer Patients to Close Ahead of Schedule
- Roche Receives Approvable Letter for Mircera in the United States
- Pfizer Says Research and Development Head John LaMattina Will Retire This Year
- Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
- Novartis Defends Its Intellectual Property Rights as US Court Issues Order Prohibiting Teva from Selling a Generic Version of Lotrel
- Questcor Announces Departure of CEO James Fares
- Champions Biotechnology, Inc. Acquires Biomerk, Inc.
- Thermo Fisher Scientific and Quintiles Create Joint Venture to Provide Integrated Response Technology Services
- GlaxoSmithKline Responds to NEJM Article on Avandia
- FDA Issues Safety Alert on Avandia
May 22, 2007
- GlaxoSmithKline Strongly Defends its Record on Avandia
- Medtronic Announces Start of 8,800-Patient Clinical Trial Evaluating Drug-Eluting Stent Safety
- Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes'
- Taro Merger with Sun Proceeds after Favorable Court Ruling in Israel
- Chairman Baucus and Ranking Member Grassley Comment on New England Journal of Medicine Report on Avandia
- FDA - MedWatch - Exjade (deferasorix) Tablets For Oral Suspension: Changes Made to The Warnings and Adverse Reactions Sections of Prescribing Information
- FDA Sends Letter to KV Pharmaceutical About Clindesse E-Mail/Alert
May 23, 2007
- Vion Announces Suspension of Phase III Trial in Relapsed AML
- DRAXIS Manufacturing Facilities Pass Extensive FDA Inspection
- Organon and Philips Team up to Study Drug Effects at the Molecular Level
- Third Point Appeals to Unconflicted Directors of PDL BioPharma; Seeks Resignation of Board Chairman as Well as CEO
- PhRMA Meets with Thai Health Minister; Highlights Consequences of Compulsory Licenses
- Medidata Solutions Achieves Largest Revenue Quarter in Company History
- FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI Images
- PhRMA Web Site Features New Drug/Patient Safety Info
- Knott Partners Expresses Concern Regarding Proposed BioVeris-Roche Transaction
May 24, 2007
- Judicial Watch Uncovers Three Deaths Relating to HPV Vaccine
- Judicial Watch Uncovers Three Deaths Relating to HPV Vaccine
- CV Therapeutics Significantly Reduces Operating Expenses
- Mylan Reports Fourth Quarter & Fiscal 2007 Adjusted Diluted EPS of $0.47 & $1.65 Excluding any Contribution from Amlodipine
- EMEA Statement on Recent Publication on Cardiac Safety of Rosiglitazone (Avandia, Avandamet, Avaglim)
- STARLIMS Technologies Ltd. Announces Public Offering of Its Ordinary Shares in the United States at a Price Per Share of $13.50 with Net Proceeds to the Company of Approximately $25.5 Million
- Neose Receives Milestone Payment From Novo Nordisk on Factor IX Program
- Annual Stockholders’ Meeting of Bayer Schering Pharma AG, Berlin, Germany: Integration of Bayer Schering Pharma Progressing Rapidly
- GlaxoSmithKline Launches Chinese R&D Centre with Appointment of Head in Shanghai
- Helicos Biosciences Prices Initial Public Offering
- Hispanics and African Americans Among Those at Risk Due to High Cost of Prescription Drugs
- FDA Sends Warning Letter to Enzon Over Abelcet Flash Card
May 25, 2007
- VaxGen Completes Development Activity in Support of Anthrax Vaccine Partnering Effort and Reduces Associated Staff
- Recall of counterfeit Zyprexa batches
- Pharma Bloggers Express Differing Opinions on Avandia Revelation and Departure of Pfizer CFO Alan Levin
- FDA Takes Action Against Unapproved Timed-Release Guaifenesin Products, Including Prescription Versions of Mucinex DM and Mucinex D
May 29, 2007
- Purdue Pharma L.P. Announces End of OxyContin Patent Lawsuit With IMPAX Laboratories
- Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway
- Bradley Pharmaceuticals Announces Receipt of 'Going Private' Proposal at $21.50 Per Share Establishment of Special Committee
- Shanghai Century Acquisition Corporation Announces Proposed Business Combination With Kelun Pharmaceutical, China's Largest Producer of IV Solution Products
- Patient Compliance: Is There a Solution? Consumers Weigh in on the Questions and Answers of Complying with Drug Regimens
May 30, 2007
- Us Court Continues to Prevent Teva from Shipping Any Additional Generic Copies of the High Blood Pressure Medicine Lotrel
- Biowa and Takeda Announce Licensing of Biowa's Potelligent Technology for Use in Antibody Research and Development
- Norwalk, Ohio Mother Sues Bayer Healthcare Pharmaceuticals for the Death of Her 24-Year-Old Son
- At $42 Billion by 2011, Immunological and BioTherapy Cancer Treatments Near 50% of Market!
- Gabelli Equity Trust Inc. Shareholders Approve Spin-off of the Gabelli Healthcare & Wellness(Rx) Trust
- Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
- Investor Alert From Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of Bradley Pharmaceuticals, Inc. - BDY
May 31, 2007
- Bristol-Myers Squibb Pleads Guilty to Lying to the Federal Government About Deal Involving Blood-Thinning Drug
- FDA Sends Warning Letter to Allergan Regarding Acular Advertisement
- Medarex Announces Collaborative Research Agreement with Mitsubishi Pharma
- Point Therapeutics Reduces Costs by Cutting Work Force
- Philadelphia Hormone Therapy Verdict Overturned in Favor of Wyeth
- inVentiv Health Acquires Addison Whitney, Full Service Global Brand Identity and Consulting Firm
- AtheroGenics Announces Business Plan to Focus on Advancing AGI-1067 in Diabetes
- Point Therapeutics Reduces Costs by Cutting Work Force
- Swissmedic Orders the Withdrawal of Zelmac for Irritable Bowel Syndrome
- KFDunn Merges with Aloysius Butler & Clark to Form New Division: KFDunn Life Sciences Marketing Communications
- Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure
- Third Point Asks Unconflicted Directors of PDL BioPharma to Conclude Investigation Into CEO McDade's Suspected Ethical and Business Breaches as Expeditiously as Possible
- FDA Finalizes Guidances For Pandemic and Seasonal Influenza Vaccines
- HealthShares Announces Changes to the HealthShares Infectious Disease, Respiratory/Pulmonary, Cancer, and Composite Indexes
